ALX Oncology Holdings Inc represents a dedication to advancing innovative cancer therapies. The company's core values include excellence, integrity, and a commitment to improving patient outcomes. ALX Oncology strives to deliver transformative treatments for patients with difficult-to-treat cancers by leveraging its expertise in developing antibodies that target the CD47/SIRPα pathway. Through a patient-centered approach and a focus on scientific rigor, ALX Oncology is working tirelessly to redefine the standard of care in oncology. With its strong corporate philosophy and cutting-edge research, ALX Oncology Holdings Inc is poised to make significant contributions to the fight against cancer.

ALX Oncology Holdings Inc is primarily present in the United States.

ALX Oncology Holdings Inc, a leading oncology-focused biotechnology company, has achieved several significant milestones in recent years. The company has made remarkable progress in advancing its innovative pipeline of novel cancer therapies. One notable achievement includes the successful completion of a Phase 1 trial for ALX148, its lead product candidate. Furthermore, ALX Oncology has forged strategic collaborations and partnerships with renowned institutions and biopharmaceutical companies, which have both supported and accelerated its research and development efforts. These milestones demonstrate ALX Oncology's commitment to pioneering breakthrough therapies that have the potential to revolutionize cancer treatment and improve patient outcomes.

ALX Oncology Holdings Inc is a biotechnology company that focuses on developing innovative therapies for the treatment of cancer. The company was founded in [year] and is headquartered in [location]. ALX Oncology Holdings Inc has a rich history of scientific advancements and collaborations with leading research institutions. With a strong team of experienced industry professionals, the company has made significant progress in developing novel cancer treatments. ALX Oncology Holdings Inc is committed to improving the lives of cancer patients and aims to revolutionize the field of oncology with its innovative therapies.

The main competitors of ALX Oncology Holdings Inc in the market include other companies specializing in the field of oncology. Some prominent competitors in the industry are Merck & Co., Inc., Bristol Myers Squibb Company, and Genentech, a member of the Roche Group. These companies also focus on developing innovative cancer treatments and therapies. ALX Oncology competes with these industry leaders by striving to differentiate itself through its unique approach, proprietary products, and research advancements in the field of oncology.

ALX Oncology Holdings Inc is primarily active in the biotechnology and healthcare industries.

ALX Oncology Holdings Inc is a biopharmaceutical company focused on developing therapies for cancer treatment. Their business model revolves around the discovery and development of novel immunotherapies that target the CD47 checkpoint pathway. By leveraging their expertise in immune modulation, ALX Oncology aims to improve the outcomes for cancer patients by harnessing the power of the immune system to selectively target and eliminate tumor cells. Through diligent research and strategic collaborations, ALX Oncology strives to bring innovative therapies to market and make a meaningful impact in the field of oncology.

مُعامل القيمة السوقية إلى الأرباح لـ ALX Oncology Holdings هو ؜-٠٫٤٥.

مُعامِل القيمة إلى المبيعات ALX Oncology Holdings هو 0.

نقاط جودة AlleAktien لـ ALX Oncology Holdings هي 2/10.

لا يمكن حالياً حساب الإيرادات لـALX Oncology Holdings.

صافي الربح المتوقعة ALX Oncology Holdings هو ؜-١٤٨٫٢٦ مليون. USD.

ALX Oncology Holdings Inc is an emerging biotechnology company with a comprehensive portfolio of innovative cancer drugs currently in various stages of clinical development. The company is headquartered in Burlingame, California and is listed on the Nasdaq under the ticker symbol "ALXO". ALX Oncology Holdings Inc relies on a business model based on extensive scientific research and development. The company specializes in developing novel approaches to cancer treatment. ALX Oncology Holdings Inc investigates complex mechanisms contributing to cancer development and the interactions between tumor cells and the immune system. ALX Oncology Holdings Inc has developed a pipeline of drug candidates that represent potentially groundbreaking therapeutic approaches for various types of cancer. Most of these compounds target PD-L1, a protein produced by tumor cells that impairs the immune system. By blocking PD-L1, immune cells can better recognize and effectively combat the tumor. One of ALX Oncology Holdings Inc's leading drug candidates is ALX148, a specific antibody against PD-L1. ALX148 is currently in multiple clinical trials for various types of cancer in clinical development. The results of the initial studies are promising, and ALX Oncology Holdings Inc plans to obtain market approval for the drug in the coming years. In addition to ALX148, ALX Oncology Holdings Inc also has other drugs in its pipeline, such as ALX5641, which targets the inhibition of an enzyme crucial for the survival of tumor cells. Furthermore, ALX Oncology Holdings Inc is working on other compounds for cancer immunotherapy and the breakdown of immune barriers in the body. ALX Oncology Holdings Inc aims to collaborate with partners and other biopharmaceutical companies to distribute its cancer drug compounds in various markets and regions worldwide. For this purpose, ALX Oncology Holdings Inc works closely with clinical research organizations, regulatory authorities, and medical professionals to validate its products and pave the way for their approval. Overall, the business model of ALX Oncology Holdings Inc is closely connected to cancer research and development. It focuses on developing unique cancer drugs that target the blockade of specific signaling pathways in tumor cells. With a strong pipeline and a multitude of clinical trials, the company strives to develop new therapeutic approaches for severe types of cancer that can impact the lives of millions of people.

يوزع ALX Oncology Holdings أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ ALX Oncology Holdings في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـALX Oncology Holdings هو US00166B1052.

رمز WKN لـ ALX Oncology Holdings هو A2P79Z.

الرمز المُختصر لـ ALX Oncology Holdings هو ALXO.

خلال آخر 12 شهراً، دفعت ALX Oncology Holdings توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع ALX Oncology Holdings خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ ALX Oncology Holdings هي .

ALX Oncology Holdings يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

ALX Oncology Holdings دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

ALX Oncology Holdings يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من ALX Oncology Holdings المُعلن عنها في ١٧‏/١٢‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٧‏/١٢‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٧‏/١٢‏/٢٠٢٤.

في العام 2023، وزعت ALX Oncology Holdings 0 USD كأرباح أسهم.

يتم توزيع أرباح ALX Oncology Holdings بالعملة USD.